FDA approved Unloxcyt (cosibelimab-ipdl) for Advanced Cutaneous Squamous Cell CarcinomaFDA approved new immunotherapy drug Unloxcyt for advanced skin cancer

Unloxcyt (cosibelimab-ipdl) is a programmed death ligand-1 (PD-L1) blocking antibody. It binds to PD-L1, preventing its interaction with PD-1 and B7.1 receptors, thereby releasing the inhibition of immune responses, including anti-tumor T-cell activity.

Unloxcyt is indicated for the treatment of adults with metastatic cutaneous squamous cell carcinoma (mCSCC) or locally advanced CSCC (laCSCC) who are not candidates for curative surgery or curative radiation.

The recommended dosage is 1,200 mg administered as an intravenous infusion over 60 minutes every 3 weeks until disease progression or unacceptable toxicity. No dose reductions are recommended. For adverse reactions, dosing modifications are specified in the label. Prepare by adding 20 mL (1,200 mg) to a 250 mL IV bag of 0.9% Sodium Chloride Injection. Administer through a sterile, in-line or add-on 0.2-micron to 0.22-micron filter. Do not administer as an IV push or bolus.

The label states that efficacy was evaluated in Study CK-301-101 (NC). Specific efficacy results (e.g., response rates, duration of response) are not provided in the label text. Trial data not available in label.

Warnings include immune-mediated adverse reactions such as pneumonitis, colitis, hepatitis, endocrinopathies, nephritis, exfoliative dermatologic conditions, myocarditis, and neurological toxicities. Infusion-related reactions may also occur. Dose modifications are recommended based on severity. No contraindications are listed in the label.

Unloxcyt provides a new PD-L1 inhibitor option for patients with advanced CSCC who are not candidates for curative surgery or radiation. It is an alternative to other checkpoint inhibitors in this setting. Clinicians should consider its place relative to existing therapies, though no comparative data are provided in the label.